TY  - GEN
AU  - García-Gutiérrez, Valentín
AU  - Gómez-Casares, María T
AU  - Puerta, José M
AU  - Alonso-Domínguez, Juan M
AU  - Osorio, Santiago
AU  - Hernández-Boluda, Juan C
AU  - Collado, Rosa
AU  - Ramírez, María J
AU  - Ibáñez, Fátima
AU  - Martín, María L
AU  - Rodríguez-Gambarte, Juan D
AU  - Martínez-Laperche, Carolina
AU  - Gómez, Montse
AU  - Fiallo, Dolly V
AU  - Redondo, Sara
AU  - Rodríguez, Alicia
AU  - Ruiz-Nuño, Concepción
AU  - Steegmann, Juan L
AU  - Jiménez-Velasco, Antonio
PY  - 2017
DO  - 10.1371/journal.pone.0173532
UR  - http://hdl.handle.net/20.500.12105/17295
AB  - In chronic myeloid leukemia (CML) patients, 3-month BCR-ABL1 levels have consistently been correlated with further outcomes. Monitoring molecular responses in CML using the GeneXpert (Cepheid) platform has shown an optimal correlation with...
LA  - eng
PB  - Public Library of Science (PLOS)
KW  - Humanos
KW  - Leucemia mielógena crónica BCR-ABL positiva
KW  - Leucemia mieloide de fase crónica
KW  - Reacción en cadena de la polimerasa
KW  - Probabilidad
KW  - Estándares de referencia
KW  - Humans
KW  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive
KW  - Leukemia, Myeloid, Chronic-Phase
KW  - Polymerase Chain Reaction
KW  - Probability
KW  - Reference Standards
TI  - A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia
TY  - research article
ER  -